Abstract:Objectives: Chemoresistance development represents a major obstacle to the successful treatment of colorectal cancer (CRC). The aim of this study was to elucidate the mechanism by which miR-506 reverses oxaliplatin chemoresistance in CRC. Methods: In this study, miR-506 levels were measured in 74 patients with colon cancer via quantitative real-time polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH). We subsequently analysed the relationship between miR-506 expression and CRC patient survival via the Kaplan-Meier method. MTT assay demonstrated the fractional survival rates and cell viability of HCT116-OxR, HCT116-OxR-miR-Ctrl and HCT116-OxR-miR-506 cells treated with oxaliplatin at different concentrations. Cell proliferation and apoptosis were assessed via flow cytometry (FCM) analysis and apoptosis assay. MDR1 mRNA expression and P-gp protein expression were assessed via qRT-PCR and Western blotting (WB) respectively. Immunofluorescence (IF) staining demonstrated P-gp expression in HCT116-OxR and HCT116-OxR-miR-506 cells. qRT-PCR and WB were used to detect Wnt/beta-catenin pathway activity after miR-506 overexpression. Results: In the present study, in ISH and qRT-PCR results demonstrated that miR-506 is weakly expressed in chemoresistant CRC tissues. The low miR-506 expression group exhibited lower 5-year OS and lower 5-year RFS than the high miR-506 expression group. miR-506 overexpression inhibited cell growth and increased oxaliplatin-induced cell apoptosis in HCT116-OxR cells, as shown via FCM and apoptosis assay. We subsequently noted low MDR1/P-gp expression in HCT116-OxR-miR-506 cells via qRT-PCR, WB and IF. Lastly, we demonstrated low MDR1/P-gp expression in HCT116-OxR-miR--506 cells via inhibition of the Wnt/beta-catenin by WB, MTT and FCM analysis. Conclusion: Taken together, the findings of our study demonstrate that miR-506 overexpression in HCT116-OxR cells enhances oxaliplatin sensitivity by inhibiting MDR1/P-gp expression via down-regulation of the Wnt/beta-catenin pathway and thus provide a rationale for the development of miRNA-based strategies to reverse oxaliplatin resistance in CRC cells.

HMGB1-mediated Autophagy Modulates Sensitivity of Colorectal Cancer Cells to Oxaliplatin Via MEK/ERK Signaling Pathway.

HMGA2 Promotes Resistance Against Paclitaxel by Targeting the P53 Signaling Pathway in Colorectal Cancer Cells

Autophagy Protects Against Oxaliplatin-Induced Cell Death Via ER Stress and ROS in Caco-2 Cells

Elevating H3K27me3 Level Sensitizes Colorectal Cancer to Oxaliplatin.

The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer

ZEB1 Promotes Oxaliplatin Resistance Through the Induction of Epithelial - Mesenchymal Transition in Colon Cancer Cells

The Akt/Gsk3 Beta-Mediated Slug Expression Contributes To Oxaliplatin Resistance In Colorectal Cancer Via Upregulation Of Ercc1

Autophagy Contributes to the Enrichment and Survival of Colorectal Cancer Stem Cells under Oxaliplatin Treatment

Exosomes Mediate the Production of Oxaliplatin Resistance and Affect Biological Behaviors of Colon Cancer Cell Lines

Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells Through Its Effects on Mir-409-3p

Role of autophagy in resistance to oxaliplatin in hepatocellular carcinoma cells.

FKBP3 Mediates Oxaliplatin Resistance in Colorectal Cancer Cells by Regulating HDAC2 Expression

Tumor-Associated Macrophages Promote Oxaliplatin Resistance via METTL3-Mediated m6A of TRAF5 and Necroptosis in Colorectal Cancer.

Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines

Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer

miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.

Autophagy Activation Contributes to Glutathione Transferase Mu 1-Mediated Chemoresistance in Hepatocellular Carcinoma.

MiR-1254 and MEGF6 Regulates Oxaliplatin Resistance in Human Colorectal Cancer Cells.

Analysis of Oxaliplatin Resistance in Colorectal Cancer Cells by Combined Proteomics and Phosphoproteomic

HMGB1 induces radioresistance through PI3K/AKT/ATM pathway in esophageal squamous cell carcinoma

Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma